Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2016

22.07.2016 | Original Article – Clinical Oncology

High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer

verfasst von: Ji Soo Park, Hong Jae Chon, Hei-Cheul Jeung, Sang Joon Shin, Sun Young Rha, Joong Bae Ahn, Kang Young Lee, Nam Kyu Kim, Hyun Cheol Chung

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy.

Methods

We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS).

Results

The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348–4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241–4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130–2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035–0.517; p = 0.003).

Conclusions

We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRefPubMed Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRefPubMed
Zurück zum Zitat Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419CrossRefPubMed Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419CrossRefPubMed
Zurück zum Zitat Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B (2015) Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 54(1):5–16CrossRefPubMed Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B (2015) Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 54(1):5–16CrossRefPubMed
Zurück zum Zitat Erlichman C, O’Connell M, Kahn M, Marsoni S, Torri V, Tardio B, Zaniboni A, Pancera G, Martignoni G, Labianca R (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17(5):1356–1363 Erlichman C, O’Connell M, Kahn M, Marsoni S, Torri V, Tardio B, Zaniboni A, Pancera G, Martignoni G, Labianca R (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17(5):1356–1363
Zurück zum Zitat Fang SH, Efron JE, Berho ME, Wexner SD (2014) Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J Am Coll Surg 219(5):1056–1069CrossRefPubMed Fang SH, Efron JE, Berho ME, Wexner SD (2014) Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J Am Coll Surg 219(5):1056–1069CrossRefPubMed
Zurück zum Zitat Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 22(16):3395–3407CrossRefPubMed Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 22(16):3395–3407CrossRefPubMed
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS (2014) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 46(2):109–123CrossRefPubMedPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS (2014) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 46(2):109–123CrossRefPubMedPubMedCentral
Zurück zum Zitat Kim GM, Ahn JB, Rha SY et al (2013) Changing treatment patterns in elderly patients with resectable colon cancer. Asia Pac J Clin Oncol 9(3):265–272CrossRefPubMed Kim GM, Ahn JB, Rha SY et al (2013) Changing treatment patterns in elderly patients with resectable colon cancer. Asia Pac J Clin Oncol 9(3):265–272CrossRefPubMed
Zurück zum Zitat Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY (2014) Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. doi:10.1002/cncr.29072 Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY (2014) Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. doi:10.​1002/​cncr.​29072
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D, Group EGW (2013) Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi64–vi72 Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D, Group EGW (2013) Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi64–vi72
Zurück zum Zitat Lin HH, Chang YY, Lin JK et al (2014) The role of adjuvant chemotherapy in stage II colorectal cancer patients. Int J Colorectal Dis 29(10):1237–1243CrossRefPubMed Lin HH, Chang YY, Lin JK et al (2014) The role of adjuvant chemotherapy in stage II colorectal cancer patients. Int J Colorectal Dis 29(10):1237–1243CrossRefPubMed
Zurück zum Zitat Ma BB, Hui EP, Mok TS (2010) Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 11(1):75–84CrossRefPubMed Ma BB, Hui EP, Mok TS (2010) Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 11(1):75–84CrossRefPubMed
Zurück zum Zitat Nedrebo BS, Soreide K, Nesbakken A, Eriksen MT, Soreide JA, Korner H, Norwegian Colorectal Cancer G (2013) Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Dis 15(6):e301–e308CrossRefPubMed Nedrebo BS, Soreide K, Nesbakken A, Eriksen MT, Soreide JA, Korner H, Norwegian Colorectal Cancer G (2013) Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Dis 15(6):e301–e308CrossRefPubMed
Zurück zum Zitat O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1):246–250PubMed O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1):246–250PubMed
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19):1420–1425CrossRefPubMed O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19):1420–1425CrossRefPubMed
Zurück zum Zitat O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ (2008) Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 26(14):2336–2341CrossRefPubMed O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ (2008) Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 26(14):2336–2341CrossRefPubMed
Zurück zum Zitat O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29(25):3381–3388CrossRefPubMedPubMedCentral O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29(25):3381–3388CrossRefPubMedPubMedCentral
Zurück zum Zitat Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M, Akagi Y, Shirouzu K (2009) Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol 99(1):65–70CrossRefPubMed Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M, Akagi Y, Shirouzu K (2009) Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol 99(1):65–70CrossRefPubMed
Zurück zum Zitat Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99(13):998–1003CrossRefPubMed Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99(13):998–1003CrossRefPubMed
Zurück zum Zitat Quah HM, Chou JF, Gonen M et al (2008) Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51(5):503–507CrossRefPubMed Quah HM, Chou JF, Gonen M et al (2008) Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51(5):503–507CrossRefPubMed
Zurück zum Zitat Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604):2020–2029CrossRef Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604):2020–2029CrossRef
Zurück zum Zitat Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704CrossRefPubMed Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704CrossRefPubMed
Zurück zum Zitat Wolmark N, Fisher B, Wieand HS et al (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199(4):375–382CrossRefPubMedPubMedCentral Wolmark N, Fisher B, Wieand HS et al (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199(4):375–382CrossRefPubMedPubMedCentral
Zurück zum Zitat Wright FC, Law CH, Berry S, Smith AJ (2009) Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol 99(4):248–255CrossRefPubMed Wright FC, Law CH, Berry S, Smith AJ (2009) Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol 99(4):248–255CrossRefPubMed
Metadaten
Titel
High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
verfasst von
Ji Soo Park
Hong Jae Chon
Hei-Cheul Jeung
Sang Joon Shin
Sun Young Rha
Joong Bae Ahn
Kang Young Lee
Nam Kyu Kim
Hyun Cheol Chung
Publikationsdatum
22.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2208-2

Weitere Artikel der Ausgabe 9/2016

Journal of Cancer Research and Clinical Oncology 9/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.